American Heart Journal
Volume 151, Issue 5 , Pages 949-955, May 2006

Management of elderly patients with congestive heart failure—Design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF)

  • Hans Peter Brunner–La Rocca, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Peter Theo Buser, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Ruth Schindler, RN

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Alain Bernheim, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
  • ,
  • Peter Rickenbacher, MD

      Affiliations

    • Division of Cardiology, Kantonsspital Bruderholz, Bruderholz, Switzerland
  • ,
  • Matthias Pfisterer, MD

      Affiliations

    • Division of Cardiology, University Hospital Basel, Basel, Switzerland
    • Corresponding Author InformationReprint requests: Matthias Pfisterer, MD, FESC, FACC, FAHA, Head Division of Cardiology, University Hospital, Petersgraben 4, CH-4031 Basel, Switzerland.
  • ,
  • for the TIME-CHF-Investigators

Received 7 July 2005; accepted 20 October 2005.

Background

Little is known about the management of elderly patients with congestive heart failure (CHF) although they represent the majority of the CHF population. Therefore, the TIME-CHF study was set up (1) to evaluate the medical management of very old patients (≥75 years) with CHF compared with younger patients (60-74 years), (2) to compare an intensified with a standard treatment approach, and (3) to differentiate between systolic and diastolic dysfunction (ejection fraction ≤45% vs >45%).

Methods

In a prospective single-blinded multicenter trial, 824 symptomatic patients, CHF hospitalization within the last year and elevated NT-BNP, are randomized to an intensified versus a standard medical therapy. Treatment strategies follow the published guidelines with the aim to reduce symptoms to NYHA class ≤II (standard) or, additionally, NT-BNP levels below twice the upper limit of normal (intensified). The primary end points are 18-month hospitalization-free survival and quality of life.

Results

By the end of 2004, 297 patients have been included, 147 randomized to intensified and 150 to standard therapy. Mean age in the older age group was 82 ± 4 years (n = 174) and 69 ± 4 years in the younger group (n = 123), respectively. Ejection fraction was >45% in 26% and 10%, respectively. Significant comorbidities were present in 93% of patients.

Conclusion

TIME-CHF will be the first prospective randomized trial to comprehensively study the management of elderly patients with CHF. It will provide unique information comparing two treatment strategies in two age groups irrespective of ejection fraction regarding prognosis, quality of life, as well as resource utilization and costs.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This study is sponsored by the Horten Foundation, Lugano, Switzerland, as well as by unrestricted grants from AstraZeneca Pharma, Menarini Pharma, Novartis Pharma, Pfizer Pharma, Servier (all Switzerland with equal contributions), Roche Diagnostics, Roche Pharma, and Merck Pharma, Switzerland.

PII: S0002-8703(05)01006-9

doi:10.1016/j.ahj.2005.10.022

American Heart Journal
Volume 151, Issue 5 , Pages 949-955, May 2006